Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.
Bullboard Posts
User Avatar Image
(6)
•••
Post by BowenQueenon May 07, 2020 1:19pm
102 Views
Post# 30998739

Algernon to begin COVID-19 human trials in South Korea

Algernon to begin COVID-19 human trials in South KoreaToday, Financial Post published an article featuring Algernon Pharmaceuticals. The article highlights their re-purposed drug, NP-120 (Ifenprodil) which has shown promise in protecting the lungs from lasting damage due to the COVID-19 virus.

"'The sobering truth about the COVID-19 virus is not if you will survive it. It is how healthy your lungs will be after you recover,' notes Christopher J. Moreau, CEO of Vancouver-based Algernon Pharmaceuticals Inc. (CSE: AGN, FRANKFURT: AGW, OTCQB: AGNPF). His company has just been approved to conduct human trials in South Korea on its re-purposed drug, NP-120 (Ifenprodil) that shows promise to protect the lungs from the COVID-19 virus."

Read the full article here: https://business.financialpost.com/business-trends/algernon-to-begin-covid-19-human-trials-in-south-korea

Find out more about Algernon Pharmaceuticals: https://algernonpharmaceuticals.com/
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities